Sarepta Therapeutics, Inc. (SRPT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Sarepta Therapeutics, Inc. (SRPT) closed at USD 16.83 on 2026-10-14, a change of -30.5 % over the past year, with a market capitalization of USD 1.88B.

Sarepta Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sarepta Therapeutics, Inc. key figures

Previous close

USD 16.83 (2026-10-14)

1-year change

-30.5 %

Market cap

USD 1.88B

Enterprise value

USD 2.15B

P/E ratio (trailing)

-11.33

P/E ratio (forward)

7.38

EPS (trailing)

-1.57

EPS (forward)

2.41

PEG ratio

-0.09

Price to book

1.23

Revenue growth

-34.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.77

Employees

835

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sarepta Therapeutics, Inc. and compare it with other stocks.